Ferroptosis plays a vital role in clinical tumour drug resistance, and its inhibitor solute carrier family 7 member 11 (SLC7A11) is a promising target to overcome resistance in conventional cancer therapy. This evidence concerns the gene SLC7A11 and neoplasm.